FGEN FibroGen Inc

39.55
+0.18  (+0%)
Previous Close 39.37
Open 38.58
Price To Book 7.13
Market Cap 3360882115
Shares 84,978,056
Volume 548,862
Short Ratio
Av. Daily Volume 633,679

SEC filingsSee all SEC filings

  1. 8-K - Current report 181224202
  2. 8-K - Current report 181218670
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181169761
  4. 8-K - Current report 181169667
  5. CT ORDER - Confidential treatment order 181169401

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 completion of enrollment announced June 7, 2018 with data due 4Q 2018. Pooled MACE safety data 1H 2019.
Roxadustat - ANDES
Anaemia in Chronic Kidney Disease
Phase 3 trial initiated 1Q 2018.
Roxadustat
Myelodysplastic syndromes (MDS)
Phase 2 enrollment completed 1Q 2018.
FG-3019
Duchenne muscular dystrophy
Phase 2 ongoing in Hong Kong. Future development uncertain
FG-3019
Liver fibrosis
Phase 3 trial to commence early 2019.
Pamrevlumab (FG-3019)
Idiopathic pulmonary fibrosis
Phase 3 trial to be initiated 1Q 2019.
Pamrevlumab (FG-3019)
Pancreatic cancer
Phase 3 Japan data noted hepcidin reduction from baseline (p=0.003) compared to epoetin alfa group (p=0.12)
Roxadustat
Chronic kidney disease

Latest News

  1. See what the IHS Markit Score report has to say about FibroGen Inc.
  2. FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors
  3. New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018
  4. Edited Transcript of FGEN earnings conference call or presentation 8-Nov-18 10:00pm GMT
  5. Today's Research Reports on Trending Tickers: Amicus Therapeutics and FibroGen
  6. FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates
  7. FibroGen: 3Q Earnings Snapshot
  8. FibroGen Reports Third Quarter 2018 Financial Results
  9. What Kind Of Shareholder Appears On The FibroGen Inc’s (NASDAQ:FGEN) Shareholder Register?
  10. FibroGen to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018
  11. ASN Kidney Week 2018: Data Presented from Two Japanese Phase 3 Studies on Roxadustat in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis
  12. FibroGen Presents Results from Two Phase 3 Studies of Roxadustat for the Treatment of Anemia Associated with Chronic Kidney Disease Conducted in China at American Society of Nephrology Kidney Week 2018 Annual Meeting
  13. Today's Research Reports on Trending Tickers: Immunomedics and FibroGen
  14. FibroGen Announces Four Clinical Presentations on Roxadustat at Upcoming American Society of Nephrology Kidney Week 2018 Annual Meeting
  15. Research Report Identifies The Habit Restaurants, Datawatch, SMART SAND INC, Independence Contract Drilling, Pareteum, and FibroGen with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  16. Analysts Remain Bullish on Intercept Pharmaceuticals
  17. Astellas Submits New Drug Application in Japan of Roxadustat for The Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis

SEC Filings

  1. 8-K - Current report 181224202
  2. 8-K - Current report 181218670
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181169761
  4. 8-K - Current report 181169667
  5. CT ORDER - Confidential treatment order 181169401
  6. 8-K - Current report 181145554
  7. 8-K - Current report 181140094
  8. CT ORDER - Confidential treatment order 181111045
  9. 8-K - Current report 181095908
  10. 8-K - Current report 181078721